Catalent (CTLT) 10-Q 14 Nov 14 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Sep. 30, 2014	Nov. 03, 2014
Document Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q1	'
Entity Registrant Name	'Catalent, Inc.	'
Entity Central Index Key	'0001596783	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding (shares)	'	123,813,614

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'
Net revenue	$418.30	$414.30
Cost of sales	293	295.1
Gross margin	125.3	119.2
Selling, general and administrative expenses	81.4	81.1
Restructuring and other	1.4	3
Operating earnings/(loss)	42.5	35.1
Interest expense, net	35.5	40.9
Nonoperating Income (Expense)	-41.3	1
Earnings/(loss) from continuing operations before income taxes	-34.3	-4.8
Income tax expense/(benefit)	-14	-6.6
Earnings/(loss) from continuing operations	-20.3	1.8
Net earnings/(loss) from discontinued operations, net of tax	0.4	-0.4
Net earnings/(loss)	-19.9	1.4
Less: Net earnings/(loss) attributable to noncontrolling interest, net of tax	-0.4	-0.1
Net earnings/(loss) attributable to Catalent	-19.5	1.5
Earnings/(loss) from continuing operations less net income (loss) attributable to noncontrolling interest	($19.90)	$1.90
Income (Loss) from Continuing Operations, Per Basic Share	($0.19)	$0.03
Earnings Per Share, Basic	($0.18)	$0.02
Income (Loss) from Continuing Operations, Per Diluted Share	($0.19)	$0.02
Earnings Per Share, Diluted	($0.18)	$0.02

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income / (Loss) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Other comprehensive income/(loss), net of tax	'	'
Net earnings/(loss)	($19.90)	$1.40
Foreign currency translation adjustments	-53.8	20.4
Pension and Other Post-Retirement adjustments	0.4	0.2
Deferred compensation	-0.2	0.5
Net current period other comprehensive income (loss)	-53.6	21.1
Comprehensive income/(loss)	-73.5	22.5
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	-0.2	-0.1
Comprehensive income/(loss) attributable to Catalent	($73.30)	$22.60

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$63.20	$74.40
Trade receivables, net	332.2	403.7
Inventories	142.4	134.8
Prepaid expenses and other	81.3	74.6
Total current assets	619.1	687.5
Property, plant, and equipment, net	853.3	873
Other assets:	'	'
Goodwill	1,057.90	1,097.10	[1]
Other intangibles, net	360.9	357.6
Deferred income taxes	24.4	26.3
Other	35.7	48.7
Total assets	2,951.30	3,090.20
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND SHAREHOLDERS' EQUITY/(DEFICIT)	'	'
Current portion of long-term obligations and other short-term borrowings	36.4	25.2
Accounts payable	116.7	148.1
Other accrued liabilities	224.5	279.7
Total current liabilities	377.6	453
Long-term Debt and Capital Lease Obligations	1,780.30	2,685.40
Pension liability	148.1	154.7
Deferred income taxes	97.6	103.2
Other liabilities	40.4	61.2
Commitment and contingencies (see Note 15)	'	'
Redeemable Noncontrolling Interest, Equity, Carrying Amount	4.3	4.5
Common stock	1.2	0.7
Additional paid in capital	1,979	1,031.40
Accumulated deficit	-1,398.60	-1,379.10
Accumulated other comprehensive income/(loss)	-77.8	-24.2
Total Shareholders' equity/(deficit)	503.8	-371.2
Noncontrolling interest	-0.8	-0.6
Total Catalent Shareholders' equity/(deficit)	503	-371.8
Total liabilities, redeemable noncontrolling interest and Shareholders' equity/(deficit)	$2,951.30	$3,090.20
[1]	The opening balance is reflective of historical impairment charges related to the Medication Delivery Solutions segment of approximately $158.0 million.

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Jun. 30, 2014
Statement of Financial Position [Abstract]	'	'
Common Stock, Par or Stated Value Per Share	$0.01	$0.01
Common Stock, Shares Authorized	1,000,000,000	84,000,000
Common stock, shares issued (shares)	123,741,468	74,821,348
Preferred Stock, Shares Authorized	100,000,000	0

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Shareholder's Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interest [Member]
In Millions, except Share data, unless otherwise specified
Beginning Balance at Jun. 30, 2014	($371.80)	$0.70	$1,031.40	($1,379.10)	($24.20)	($0.60)
Common Stock, Shares, Outstanding	123,741,468	'	'	'	'	'
Equity Contribution, Number of Shares	48,920,200	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Equity contribution	946.6	0.5	946.1	'	'	'
Equity compensation	1.5	'	1.5	'	'	'
Net Income (Loss) Attributable to Parent	-19.5	'	'	-19.5	'	'
Net Income (Loss) Attributable to Noncontrolling Interest	'	'	'	'	'	-0.2
Net earnings/(loss)	-19.7	'	'	'	'	'
Other comprehensive income/(loss), net of tax	-53.6	'	'	'	-53.6	'
Ending Balance at Sep. 30, 2014	$503	$1.20	$1,979	($1,398.60)	($77.80)	($0.80)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'		'
Net earnings/(loss)	($19.90)		$1.40
Net earnings/(loss) from discontinued operations	0.4		-0.4
Earnings/(loss) from continuing operations	-20.3		1.8
Adjustments to reconcile (loss)/earnings from continued operations to net cash from operations:	'		'
Depreciation and amortization	35		36.5
Non-cash foreign currency transaction (gain)/loss, net	-11.2		-4
Amortization and write off of debt financing costs	12.4		3.1
Business Combination, Bargain Purchase, Gain Recognized, Amount Net of Tax	7	[1]	0	[1]
Reclassification Of Call Premium Payment	9.8		0
Equity compensation	1.5		1.2
Increase (Decrease) in Deferred Income Taxes	7.7		5.3
Provision for bad debts and inventory	1.7		1.9
Change in operating assets and liabilities:	'		'
Decrease/(increase) in trade receivables	62		67.8
Decrease/(increase) in inventories	-14.1		-4
Increase/(decrease) in accounts payable	-26.3		-30.1
Other accrued liabilities and operating items, net	-76		-43.2
Net cash provided by/(used in) operating activities from continuing operations	-40.2		25.7
Net cash provided by/(used in) operating activities from discontinued operations	0.4		-0.5
Net cash provided by/(used in) operating activities	-39.8		25.2
CASH FLOWS FROM INVESTING ACTIVITIES:	'		'
Acquisition of property and equipment and other productive assets	-31.2		-18.8
Proceeds from sale of property and equipment	0		0.6
Payment for acquisitions, net	-13.5		-8
Net cash provided by/(used in) investing activities from continuing operations	-44.7		-26.2
Net cash provided by/(used in) investing activities from discontinued operations	0		0
Net cash provided by/(used in) investing activities	-44.7		-26.2
CASH FLOWS FROM FINANCING ACTIVITIES:	'		'
Net change in short-term borrowings	11.7		-5.8
Proceeds from borrowing, net	0		0
Payments related to long-term obligations	-863.8		-6.7
Call Premium Paid For Redemption Of Debt	9.8		0
Equity contribution/(redemption)	948.8		0
Net cash (used in)/provided by financing activities from continuing operations	86.9		-12.5
Net cash (used in)/provided by financing activities from discontinued operations	0		0
Net cash (used in)/provided by financing activities	86.9		-12.5
Effect of foreign currency on cash	-13.6		2.9
NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS	-11.2		-10.6
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD	74.4		106.4
CASH AND EQUIVALENTS AT END OF PERIOD	63.2		95.8
SUPPLEMENTARY CASH FLOW INFORMATION:	'		'
Interest paid	44.3		23.8
Income taxes paid, net	$9.90		$15.80
[1]	-1

Basis_of_Presentation_and_Summ

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Summary of Significant Accounting Policies	'
	BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Business
	Catalent, Inc. (“Catalent” or the “Company”) directly and wholly owns PTS Intermediate Holdings LLC (“Intermediate Holdings”). Intermediate Holdings directly and wholly owns Catalent Pharma Solutions, Inc. (“Operating Company”). The financial results of Catalent are solely comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis.
	In July 2014, the Company’s board of directors and holders of the requisite number of outstanding shares of its capital stock approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 70-for-1 stock split of its outstanding common stock (the “stock split”). The stock split became effective on July 17, 2014 upon the filing of the Company’s Certificate of Amendment of the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State. On the effective date of the stock split, (i) each outstanding share of common stock was increased to seventy shares of common stock, (ii) the number of shares of common stock issuable under each outstanding option to purchase common stock was proportionately increased on a one-to-seventy basis, (iii) the exercise price of each outstanding option to purchase common stock was proportionately decreased on a one-to-seventy basis, and (iv) the number of shares underlying each restricted stock unit was proportionately increased on a one-to-seventy basis. All of the share and per share information referenced throughout the financial statements and notes to the financial statements have been retroactively adjusted to reflect this stock split.
	On August 5, 2014, the Company completed an initial public offering (the "IPO") of 42.5 million shares of its common stock for an initial price of $20.50 per share for total proceeds, before underwriting discounts and commissions and other offering expenses of approximately $871.3 million and proceeds net of underwriters discount and commissions of approximately $828 million. The shares offered and sold in the IPO were registered under the Securities Act pursuant to the Company's Registration Statement on Form S-1 (File No. 333-193542), which was declared effective by the SEC on July 30, 2014. The proceeds raised were used to pay an advisory agreement termination fee of $29.8 million to Blackstone and certain other existing owners recorded within other (income)/expense, net on the Consolidated Statements of Operations, redeem the outstanding Senior Subordinated Notes, and redeem the outstanding Senior Notes. The remaining proceeds were used to repay portions of the unsecured term loan. The Company's common stock began trading on the New York Stock Exchange under the symbol "CTLT" as of July 31, 2014. On September 9, 2014, Morgan Stanley and J.P. Morgan, as representatives of the underwriters of Catalent’s IPO, purchased an additional 6.4 million shares of Catalent’s common stock from Catalent at the initial public offering price of $20.50 per share less the underwriting discount pursuant to an option granted to the underwriters at the time of the IPO. The net proceeds received by the Company were $124.2 million and were subsequently used for debt reduction and general corporate purposes. Refer to Note 4 for further discussion regarding debt repayments.
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending June 30, 2015. The consolidated balance sheet at June 30, 2014 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2014 filed with the Securities and Exchange Commission.
	Noncontrolling interest is included within the equity section in the consolidated balance sheets. Redeemable noncontrolling interest has been classified as temporary equity and is therefore reported outside of permanent equity on the consolidated balance sheets at the greater of the initial carrying amount adjusted for the noncontrolling interest's share of net earnings/(loss) or its redemption value. The Company presents the amount of consolidated net earnings/(loss) that is attributable to Catalent and the noncontrolling interest in the consolidated statements of operations. Furthermore, the Company discloses the amount of comprehensive income that is attributable to Catalent and the noncontrolling interest in the consolidated statements of comprehensive income/(loss).
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, inventory and long-lived asset valuation, goodwill and other intangible asset valuation and impairment, equity-based compensation, income taxes, derivative financial instruments and pension plan asset and liability valuation. Actual amounts may differ from these estimated amounts.
	Foreign Currency Translation
	The financial statements of the Company’s operations outside the U.S. are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign operations into U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. The currency fluctuations related to certain long-term inter-company loans deemed to not be repayable in the foreseeable future have been recorded within the cumulative translation adjustment, a component of other comprehensive income/(loss). In addition, the currency fluctuation associated with the portion of the Company’s euro-denominated debt designated as a net investment hedge is included as a component of other comprehensive income/(loss). Foreign currency transaction gains and losses calculated by utilizing weighted average exchange rates for the period are included in the consolidated statements of operations in the other (income) expense, net line item. Foreign currency translation gains and losses generated from inter-company loans that are long-term in nature, but may be repayable in the foreseeable future, are also recorded within the other (income) expense, net line item on the consolidated statements of operations.
	Revenue Recognition
	In accordance with Codification Standard ASC 605 Revenue Recognition, the Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. In cases where the Company has multiple contracts with the same customer, the Company evaluates those contracts to assess if the contracts are linked or are separate arrangements. Factors the Company considers include the timing of negotiation, interdependency with other contracts or elements and payment terms. The Company and its customers generally view each contract discussion as a separate arrangement.
	Manufacturing and packaging service revenue is recognized upon delivery of the product in accordance with the terms of the contract, which specify when transfer of title and risk of loss occurs. Some of the Company’s manufacturing contracts with its customers have annual minimum purchase requirements. At the end of the contract year, revenue is recognized for the unfilled purchase obligation in accordance with the contract terms. Development service contracts generally take the form of a fee-for-service arrangement. After the Company has evidence of an arrangement, the price is determinable and there is a reasonable expectation regarding payment, the Company recognizes revenue at the point in time the service obligation is completed and accepted by the customer. Examples of output measures include a formulation report, analytical and stability testing, clinical batch production or packaging and the storage and distribution of a customer’s clinical trial material. Development service revenue is primarily driven by the Company’s Development and Clinical Services segment.
	Arrangements containing multiple elements, including service arrangements, are accounted for in accordance with the provisions of ASC 605-25 Revenue Recognition: Multiple-Element Arrangements. The Company determines the separate units of account in accordance with ASC 605-25. If the deliverable meets the criteria of a separate unit of accounting, the arrangement consideration is allocated to each element based upon its relative selling price. In determining the best evidence of selling price of a unit of account the Company utilizes vendor-specific objective evidence (“VSOE”), which is the price the Company charges when the deliverable is sold separately. When VSOE is not available, management uses relevant third-party evidence (“TPE”) of selling price, if available. When neither VSOE nor TPE of selling price exists, management uses its best estimate of selling price.
	Goodwill
	The Company accounts for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350 Goodwill, Intangible and Other Assets. Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. The Company's annual goodwill impairment test was conducted as of April 1, 2014. The Company assesses goodwill for possible impairment by comparing the carrying value of its reporting units to their fair values. The Company determines the fair value of its reporting units utilizing estimated future discounted cash flows and incorporates assumptions that it believes marketplace participants would utilize. In addition, the Company uses comparative market information and other factors to corroborate the discounted cash flow results.
	Property and Equipment and Other Definite Lived Intangible Assets
	Property and equipment are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following ranges of useful lives for its property and equipment categories: buildings and improvements - 5 to 50 years; machinery and equipment - 3 to 10 years; and furniture and fixtures - 3 to 7 years. Depreciation expense was $23.7 million for the three months ended September 30, 2014 and $26.2 million for the three months ended September 30, 2013. Depreciation expense includes amortization of assets related to capital leases. The Company charges repairs and maintenance costs to expense as incurred. The amount of capitalized interest was immaterial for all periods presented.
	Intangible assets with finite lives, primarily including customer relationships and patents and trademarks continue to be amortized over their useful lives. The Company evaluates the recoverability of its other long-lived assets, including amortizing intangible assets, if circumstances indicate impairment may have occurred pursuant to ASC 360 Property, Plant and Equipment. This analysis is performed by comparing the respective carrying values of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, the carrying value of such assets is reduced to fair value through a charge to the consolidated statements of operations. Fair value is determined based on assumptions the Company believes marketplace participants would utilize and comparable marketplace information in similar arms length transactions. The Company did not record any impairment charge for the three months ended September 30, 2014 or three months ended September 30, 2013.
	Research and Development Costs
	The Company expenses research and development costs as incurred. Costs incurred in connection with the development of new offerings and manufacturing process improvements are recorded within selling, general and administrative expenses. Such research and development costs included in selling, general and administrative expenses amounted to $2.8 million for the three months ended September 30, 2014 and $3.4 million for the three months ended September 30, 2013. Costs incurred in connection with research and development services the Company provides to customers and services performed in support of the commercial manufacturing process for customers are recorded within cost of sales. Such research and development costs included in cost of sales amounted to $8.8 million for the three months ended September 30, 2014 and $7.4 million for the three months ended September 30, 2013.
	Earnings / (Loss) Per Share
	The Company reports net earnings (loss) per share pursuant to ASC 260 Earnings per Share. Under ASC 260, basic earnings per share, which excludes dilution, is computed by dividing net earnings or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution of securities that could be exercised or converted into common shares, and is computed by dividing net earnings or loss available to common stockholders by the weighted average of common shares outstanding plus the dilutive potential common shares. Diluted earnings per share includes in-the-money stock options, restricted stock units, and restricted stock using the treasury stock method. During a loss period, the assumed exercise of in-the-money stock options has an anti-dilutive effect and therefore, these instruments are excluded from the computation of dilutive earnings per share.
	Equity-Based Compensation
	The Company accounts for its equity-based compensation awards pursuant to ASC 718 Compensation-Stock Compensation. ASC 718 requires companies to recognize compensation expense using a fair value based method for costs related to share-based payments including stock options and restricted stock units. The expense is measured based on the grant date fair value of the awards that are expected to vest, and the expense is recorded over the applicable requisite service period. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price based on peer companies, the expected dividends on the underlying shares and the risk-free interest rate.
	Recent Financial Accounting Standards
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which explicitly requires management to assess an entity’s ability to continue as a going concern at each annual and interim reporting period, and to provide related footnote disclosures in certain circumstances. The standard indicates that substantial doubt exists when it is probable that an entity will not meet its obligations one year from the date the financial statements are issued. The likelihood threshold of probable is similar to its current use in US GAAP for loss contingencies. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier application is permitted. Catalent does not expect this standard to have a material impact on the Company's disclosures.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09").  The new standard will supersede nearly all existing revenue recognition guidance.  The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, the standard creates a five-step model that requires a company to exercise judgment when considering the terms of the contracts and all relevant facts and circumstances.  The five steps require a company to identify customer contracts, identify the separate performance obligations, determine the transaction price, allocate the transaction price to the separate performance obligations and recognize revenue when each performance obligation is satisfied. The standard is effective for public entities for annual and interim periods beginning after December 15, 2016.  The standard allows for either full retrospective adoption, where the standard is applied to all periods presented, or modified retrospective adoption where the standard is applied only to the most current period presented in the financial statements.  Early adoption is not permitted.  Catalent is currently evaluating the impact of this standard on the Company's consolidated results of operations and financial position.

Goodwill

Goodwill	3 Months Ended
	Sep. 30, 2014
Goodwill Disclosure [Abstract]	'
Goodwill	'
	GOODWILL
	The following table summarizes the changes between June 30, 2014 and September 30, 2014 in the carrying amount of goodwill in total and by reporting segment:
	(Dollars in millions)	Oral			Medication		Development			Total
		Technologies			Delivery		& Clinical
					Solutions		Services
	Balance at June 30, 2014 (1)	$	891.8		$	—	$	205.3		$	1,097.10
	Additions/(impairments)	—			—		—			—
	Foreign currency translation adjustments	(32.0		)	—		(7.2		)	(39.2		)
	Balance at September 30, 2014	$	859.8		$	—	$	198.1		$	1,057.90
	-1	The opening balance is reflective of historical impairment charges related to the Medication Delivery Solutions segment of approximately $158.0 million.
	No goodwill impairment charges were required during the current or comparable prior year period. When required, impairment charges are recorded within the consolidated statements of operations as impairment charges and (gain)/loss on sale of assets.

Definite_Lived_LongLived_Asset

Definite Lived Long-Lived Assets	3 Months Ended
	Sep. 30, 2014
Intangible Assets Disclosure [Abstract]	'
Definite Lived Long-Lived Assets	'
	DEFINITE LIVED LONG-LIVED ASSETS
	The Company’s definite lived long-lived assets include property, plant and equipment as well as other intangible assets with definite lives. Refer to Note 17 Supplemental Balance Sheet Information for details related to property, plant and equipment.
	The details of other intangible assets subject to amortization as of September 30, 2014 and June 30, 2014, are as follows:
	(Dollars in millions)	Weighted Average Life		Gross				Accumulated				Net
				Carrying				Amortization				Carrying
				Value								Value
	30-Sep-14
	Amortized intangibles:
	Core technology	19 years		$	169.5			$	(53.5	)		$	116
	Customer relationships	14 years		229				(70.4		)		158.6
	Product relationships	12 years		230				(143.7		)		86.3
	Total intangible assets			$	628.5			$	(267.6	)		$	360.9
	(Dollars in millions)	Weighted Average Life		Gross				Accumulated				Net
				Carrying				Amortization				Carrying
				Value								Value
	30-Jun-14
	Amortized intangibles:
	Core technology	20 years		$	150.2			$	(53.3	)		$	96.9
	Customer relationships	14 years		234.6				(68.0		)		166.6
	Product relationships	12 years		237.6				(143.5		)		94.1
	Total intangible assets			$	622.4			$	(264.8	)		$	357.6
	Amortization expense was $11.3 million and $10.3 million for the three months ended September 30, 2014 and September 30, 2013, respectively. Future amortization expense is estimated to be:
	(Dollars in millions)	Remainder				2016				2017				2018		2019		2020
		Fiscal 2015
	Amortization expense	$	33.7			$	44.9			$	44.3			$	44.2	$	38.6	$	23.3
	There were no impairments of intangible assets recorded in the current or prior period.

LongTerm_Obligations_and_Other

Long-Term Obligations and Other Short-Term Borrowings	3 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Long-Term Obligations and Other Short-Term Borrowings	'
	LONG-TERM OBLIGATIONS AND OTHER SHORT-TERM BORROWINGS
	Long-term obligations and other short-term borrowings consist of the following at September 30, 2014 and June 30, 2014:
	(Dollars in millions)	Maturity	September 30,		June 30,
			2014		2014
	Senior Secured Credit Facilities
	Term loan facility dollar-denominated	May-21	1,381.00		1,383.90
	Term loan facility euro-denominated	May-21	315.6		338.6
	9 3/4 % Senior Subordinated euro-denominated Notes	Apr-17	—		293.9
	7 7/8 % Senior Notes	Oct-18	—		348.7
	Senior Unsecured Term Loan Facility	Dec-17	40.4		274.3
	$200.0 million Revolving Credit Facility	May-19	—		—
	Capital lease obligations	2015 to 2032	61.2		64
	Other obligations	2015 to 2018	18.5		7.2
	Total		1,816.70		2,710.60
	Less: Current portion of long-term obligations and other short-term borrowings		36.4		25.2
	Long-term obligations, less current portion		$	1,780.30	$	2,685.40
	Redemption of Notes and Unsecured Term Loan Prepayment
	On July 29, 2014, Operating Company provided notice of its election to redeem all of the $350.0 million aggregate principal amount outstanding of the Senior Notes. The Senior Notes were redeemed on August 28, 2014 at a redemption price of 101.5% of their principal amount plus accrued and unpaid interest. The redemption was funded with proceeds from the IPO. In connection with the redemption the Company recorded $5.3 million in expense related to the call premium and expensed $5.9 million of unamortized debt discount and deferred financing costs, both in other (income) / expense, net in the consolidated statements of operations.
	On August 5, 2014, Operating Company provided notice of its election to redeem all of the €225.0 million aggregate principal amount outstanding of the Senior Subordinated Notes. The Senior Subordinated Notes were redeemed on September 4, 2014 at a redemption price of 101.625% of their principal amount plus accrued and unpaid interest. The redemption was funded with proceeds from the IPO. In connection with the redemption the Company recorded $4.5 million in expense related to the call premium and expensed $4.0 million of unamortized debt discount and deferred financing costs, both in other (income) / expense, net in the consolidated statements of operations.
	On August 6, 2014, the Company paid $114.5 million of the outstanding borrowings under the unsecured term loans with proceeds from the IPO. On September 12, 2014, the Company repaid $120.0 million of the outstanding borrowings under the unsecured term loans with proceeds from the additional shares purchased by the representatives of the underwriters in connection with the IPO. In connection with the debt payments, the Company expensed $0.9 million of unamortized debt discount and deferred financing costs in other (income) / expense, net in the consolidated statements of operations.
	Debt Covenants
	The Credit Agreement and the senior unsecured term loan facility contain a number of covenants that, among other things, restrict, subject to certain exceptions, the Company’s (and the Company’s restricted subsidiaries’) ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans or advances; make certain acquisitions; and in the case of the Company’s Credit Agreement, enter into sale and leaseback transactions, amend material agreements governing the Company’s subordinated indebtedness and change the Company’s lines of business.
	The Credit Agreement and the senior unsecured term loan facility also contain change of control provisions and certain customary affirmative covenants and events of default. The revolving credit facility requires compliance with a Net Leverage covenant when there is a 30% or more draw outstanding at a period end. As of September 30, 2014, the Company was in material compliance with all covenants related to its long-term obligations.

Earnings_Per_Share_Notes

Earnings Per Share (Notes)	3 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	EARNINGS PER SHARE
	The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three months ended September 30, 2014 and 2013 are as follows (in millions, except per share data):
		Three months ended September 30,
	(Dollars in millions)	2014			2013
	Earnings / (loss) from continuing operations less net income / (loss) attributable to noncontrolling interest	$	(19.9	)	$	1.9
	Earnings / (loss) from discontinued operations	0.4			(0.4		)
	Net earnings / (loss) attributable to Catalent	$	(19.5	)	$	1.5
	Weighted average shares outstanding	105,535,385			75,015,223
	Dilutive securities issuable-stock plans	—			1,034,605
	Total weighted average diluted shares outstanding	105,535,385			76,049,828
	Basic earnings per share of common stock:
	Earnings / (loss) from continuing operations	$	(0.19	)	$	0.03
	Earnings / (loss) from discontinued operations	0.01			(0.01		)
	Net earnings / (loss) attributable to Catalent	$	(0.18	)	$	0.02
	Diluted earnings per share of common stock-assuming dilution:
	Earnings / (loss) from continuing operations	$	(0.19	)	$	0.02
	Earnings / (loss) from discontinued operations	0.01			—
	Net earnings / (loss) attributable to Catalent	$	(0.18	)	$	0.02
	The computation of diluted earnings per share for the three months ended September 30, 2014 excludes the maximum effect of the potential common shares issuable under the employee stock option plan of approximately 6.8 million shares, and excludes restricted share awards of 1.4 million shares, because the Company had a net loss for the period and the effect would therefore be anti-dilutive. The computation of diluted earnings per share for September 30, 2013 excludes the effect of potential shares issuable under the employee stock option plan of 2.4 million shares, because the vesting provisions of those awards specify performance or market-based conditions that had not been met as of the period end.

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activities	3 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments and Hedging Activities	'
	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
	Risk Management Objective of Using Derivatives
	The Company is exposed to fluctuations in the applicable exchange rate on its investments in foreign operations. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated the exposure of its investments in its European operations by denominating a portion of its debt in euros. At September 30, 2014, the Company had euro-denominated debt outstanding of $315.6 million that qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of the translation gains or losses are reported in accumulated other comprehensive income/(loss) as part of the cumulative translation adjustment. For the three months ended September 30, 2014, the Company recorded an unrealized foreign exchange gain of $10.8 million within cumulative translation adjustment. For the three months ended September 30, 2013, the Company recorded an unrealized foreign exchange loss of $11.4 million within cumulative translation adjustment. The net accumulated gain of this net investment as of September 30, 2014 included within other comprehensive income/(loss) was approximately $60.2 million.
	For the three months ended September 30, 2014, the Company recognized an unrealized foreign exchange gain of $21.3 million in the consolidated statement of operations related to a portion of its euro-denominated debt not designated as a net investment hedge. For the three months ended September 30, 2013, the Company recorded an unrealized foreign exchange loss of $7.6 million.
	Amounts are reclassified out of accumulated other comprehensive income/(loss) into earnings when the entity to which the gains and losses reside is either sold or substantially liquidated.

Fair_Value_Measurements_Of_Fin

Fair Value Measurements Of Financial Instruments	3 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements Of Financial Instruments	'
	FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS
	ASC 820 Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.
	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.
	Fair value under ASC 820 is principally applied to financial assets and liabilities, which, for Catalent, primarily include investments in money market funds and contingent consideration. The Company is not required to apply all the provisions of ASC 820 to the nonfinancial assets and nonfinancial liabilities. There was no change from the previously reported classification of financial assets and liabilities included in its financial statements.
	The following table provides a summary of financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall:
				Fair Value Measurements using:
	(Dollars in millions)	Total		Level 1		Level 2		Level 3
	Assets
	Cash equivalents - money market funds	$	4.1	$	4.1	$	—	$	—
	The following table provides a summary of financial assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2014, aggregated by the level in the fair value hierarchy in which those measurements fall:
				Fair Value Measurements using:
	(Dollars in millions)	Total		Level 1		Level 2		Level 3
	Assets
	Cash equivalents - money market funds	$	1.4	$	1.4	$	—	$	—
	Liabilities
	Contingent consideration	$	0.9	$	—	$	—	$	0.9
	Cash Equivalents
	The fair value of cash equivalents is estimated on the quoted market price of the investments. The carrying amounts of the Company’s cash equivalents approximate their fair value due to the short-term maturity of these instruments.
	Contingent Consideration
	The fair value of the contingent consideration, which is considered a Level 3 liability, is based on a discounted cash flow model to estimate the potential payout related to the arrangement.
	Long-Term Obligations
	The estimated fair value of long-term debt, which is considered a Level 2 liability, is based on the quoted market prices for the same or similar issues or on the current rates offered for debt of the same remaining maturities and considers collateral, if any.
	The carrying amounts and the estimated fair values of financial instruments as of September 30, 2014 and June 30, 2014, are as follows:
		30-Sep-14				30-Jun-14
	(Dollars in millions)	Carrying		Estimated Fair		Carrying		Estimated Fair
		Value		Value		Value		Value
	Long-term debt and other	$	1,816.70	$	1,839.30	$	2,710.60	$	2,680.20

Income_Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	INCOME TAXES
	The Company accounts for income taxes in accordance with the provision of ASC 740 Income Taxes. Generally, fluctuations in the effective tax rate are primarily due to changes in U.S. and non-U.S. pretax income resulting from the Company’s business mix and changes in the tax impact of special items and other discrete tax items, which may have unique tax implications depending on the nature of the item. Such discrete items include, but are not limited to, changes in foreign statutory tax rates, the amortization of certain assets and the tax impact of changes in its ASC 740 unrecognized tax benefit reserves. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world, including such major jurisdictions as the United States, Germany, France, and the United Kingdom. The Company is no longer subject to non-U.S. income tax examinations for years prior to 2005. Under the terms of the purchase agreement related to the 2007 acquisition, the Company is indemnified by its former owner for tax liabilities that may arise in the future that relate to tax periods prior to April 10, 2007. The indemnification agreement includes, among other taxes, any and all federal, state and international income-based taxes as well as related interest and penalties. As of September 30, 2014 and June 30, 2014, approximately $2.3 million and $2.4 million, respectively, of unrecognized tax benefit is subject to indemnification by the Company's former owner.
	ASC 740 includes guidance on the accounting for uncertainty in income taxes recognized in the financial statements. This standard also provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeal or litigation process, based on the technical merits. As of September 30, 2014, the Company had a total of $56.4 million of unrecognized tax benefits. A reconciliation of its reserves for uncertain tax positions, excluding accrued interest and penalties, for September 30, 2014 is as follows:
	(Dollars in millions)
	Balance at June 30, 2014	$	60.6
	Reductions based on tax positions related to the current year	(1.8		)
	Reductions for tax positions of prior years	(2.4		)
	Balance at September 30, 2014	$	56.4
	As of September 30, 2014 and June 30, 2014, the Company had a total of $61.7 million and $65.7 million, respectively, of uncertain tax positions (including accrued interest and penalties). As of these dates, $41.0 million and $41.4 million, respectively, represent the amount of unrecognized tax benefits, which, if recognized, would favorably affect the effective income tax rate. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. As of September 30, 2014 and June 30, 2014, the Company has approximately $5.4 million and $5.1 million, respectively, of accrued interest and penalties related to uncertain tax positions. As of these dates, the portion of such interest and penalties subject to indemnification by its former owner is $2.0 million and $2.0 million, respectively.

Employee_Retirement_Benefit_Pl

Employee Retirement Benefit Plans	3 Months Ended
	Sep. 30, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Employee Retirement Benefit Plans	'
	EMPLOYEE RETIREMENT BENEFIT PLANS
	Components of the Company’s net periodic benefit costs are as follows:
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Components of net periodic benefit cost:
	Service cost	$	0.7		$	0.7
	Interest cost	3.1			3
	Expected return on plan assets	(2.8		)	(2.5		)
	Amortization (1)	0.5			0.3
	Net amount recognized	$	1.5		$	1.5
	-1	Amount represents the amortization of unrecognized actuarial gains/(losses).
	The Company has recorded $39.6 million in obligations related to its withdrawal from a multi-employer pension plan related to a former commercial packaging site, a clinical services site and a former printed components operation. The estimated discounted value of the projected contributions related to these plans is $39.6 million as of September 30, 2014 and $39.6 million as of June 30, 2014. The annual cash impact associated with the Company's long-term obligation approximates $1.7 million per year. Refer to Note 15 to the Consolidated Financial Statements for further discussion.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	RELATED PARTY TRANSACTIONS
	Advisor Transaction and Management Fees
	The Company entered into a transaction and advisory fee agreement with affiliates of Blackstone and certain other investors in BHP PTS Holdings L.L.C. (the “Investors”), the investment entity controlled by affiliates of Blackstone that was formed in connection with the Investors' investment in Catalent. The Company historically paid an annual sponsor advisory fee to Blackstone and the Investors for certain monitoring, advisory and consulting services to the Company prior to the IPO. For the three months ended September 30, 2014 and September 30, 2013, this management fee was approximately $0 and $3.2 million, respectively. This fee was recorded as expense within selling, general and administrative expenses in the Consolidated Statements of Operations. In connection with the IPO, the Company paid the Investors an advisory agreement termination fee of $29.8 million in August 2014 recorded within other (income)/expense, net line item in the consolidated statements of operations.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Accumulated Other Comprehensive Income (Loss)	'
	ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)
	Description of Capital Stock and Initial Public Offering
	The Company is authorized to issue 1,000,000,000 shares of common stock, with a par value of $0.01 per share, and 100,000,000 shares of preferred stock, par value $0.01 per share. In accordance with the Company's amended and restated certificate of incorporation, each share of common stock shall have one vote, and the common stock shall vote together as a single class. In July 2014, the Company’s board of directors and holders of the requisite number of outstanding shares of its capital stock have approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 70-for-1 stock split. The stock split became effective on July 17, 2014 upon the filing with the Delaware Secretary of State of an amendment to the Company's amended and restated certificate of incorporation. Refer to Note 1 to the Consolidated Financial Statements for further discussion.
	On August 5, 2014, the Company completed an IPO of 42.5 million shares of its common stock for an initial price of $20.50 per share for total proceeds, before underwriting discounts and commissions and other offering expenses of approximately $871.3 million and proceeds net of underwriters discount and commissions of approximately $828.0 million. The shares offered and sold in the IPO were registered under the Securities Act pursuant to the Company's Registration Statement on Form S-1 (File No. 333-193542), which was declared effective by the SEC on July 30, 2014. The Company's common stock began trading on the New York Stock Exchange under the symbol "CTLT" as of July 31, 2014. On September 9, 2014, Morgan Stanley and J.P. Morgan, as representatives of the underwriters of Catalent’s IPO of its common stock, purchased an additional 6.4 million shares of Catalent’s common stock from Catalent at the IPO price of $20.50 per share less the underwriting discount for net proceeds of approximately $124.2 million pursuant to an option granted to the underwriters at the time of the IPO.
	Accumulated other comprehensive income/(loss)
	The components of the changes in the cumulative translation adjustment and minimum pension liability for the three months ended September 30, 2014 and September 30, 2013 are presented below.
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Foreign currency translation adjustments:
	Net investment hedge	$	10.8		$	(11.4	)
	Long term intercompany loans	(9.6		)	12.2
	Translation adjustments	(55.4		)	19.6
	Total foreign currency translation adjustment, pre tax	(54.2		)	20.4
	Tax expense/(benefit)	(0.4		)	—
	Total foreign currency translation adjustment, net of tax	$	(53.8	)	$	20.4
	Net change in minimum pension liability
	Net gain/(loss) recognized during the period	0.5			0.3
	Total pension, pretax	0.5			0.3
	Tax expense/(benefit)	(0.1		)	(0.1		)
	Net change in minimum pension liability, net of tax	$	0.4		$	0.2
	Changes in Accumulated Other Comprehensive Income/(Loss) by Component
	For the three months ended September 30, 2014 the changes in accumulated other comprehensive income net of tax by component are as follows:
	(Dollars in millions)	Foreign Exchange Translation Adjustments			Pension and Other Post-Retirement Adjustments			Deferred Compensation			Total
	Balance at June 30, 2014	$	14		$	(41.4	)	$	3.2		$	(24.2	)
	Other comprehensive income/(loss) before reclassifications	(53.8		)	—			(0.2		)	(54.0		)
	Amounts reclassified from accumulated other comprehensive income	—			0.4			—			0.4
	Net current period other comprehensive income (loss)	(53.8		)	0.4			(0.2		)	(53.6		)
	Balance at September 30, 2014	$	(39.8	)	$	(41.0	)	$	3		$	(77.8	)
	For the three months ended September 30, 2014, the Company reclassified $0.4 million of actuarial losses (net of tax benefit of $0.1 million) related to its defined benefit pension and other post-retirement benefit plans from accumulated other comprehensive income into selling, general and administrative expenses.

Equity_Based_Compensation_Note

Equity Based Compensation (Notes)	3 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Equity Based Compensation	'
	EQUITY-BASED COMPENSATION
	2007 Stock Incentive Plan
	The Company’s stock-based compensation is comprised of stock options and restricted stock units. Awards issued under the 2007 PTS Holdings Corp. Stock Incentive Plan, as amended (the “2007 Plan”) were generally issued for the purpose of retaining key employees and directors. The Company has adopted two forms of non-qualified stock option agreements (the “Form Option Agreement”) for awards granted under the 2007 Plan. Under the Company's Form Option Agreement adopted in 2009, a portion of the stock option awards vest in equal annual installments over a five-year period contingent solely upon the participant’s continued employment with the Company, or one of its subsidiaries, another portion of the stock option awards will vest over a specified performance period upon achievement of pre-determined operating performance targets over time and the remaining portion of the stock option awards will vest upon realization of certain internal rates of return or multiple of investment goals. Under the Company's other Form Option Agreement, adopted in 2013, a portion of the stock option awards will vest over a specified performance period upon achievement of pre-determined operating performance targets over time while the other portion of the stock option awards will vest upon realization of a specified multiple of investment goal. The Form Option Agreements include certain forfeiture provisions upon a participant’s separation from service with the Company. Following the IPO, the Company decided not to grant any further award under the 2007 Plan; however, all outstanding awards granted prior to the IPO remained outstanding in accordance with the terms of the 2007 Plan.
	2014 Omnibus Incentive Plan
	In connection with the IPO, the Company's Board of Directors adopted the 2014 Omnibus Incentive Plan effective July 30, 2014. The 2014 Plan provides certain members of management, employees and directors of the Company and its subsidiaries with various incentives, including grants of stock options and restricted stock units. A maximum of 6,700,000 shares of common stock may be issued under this plan.
	Restricted stock units under the 2014 Plan may be granted to members of management and directors. At the IPO, the Company granted to members of management restricted stock units that had certain performance-related vesting requirements ("performance stock units"). These performance stock units had a grant date fair value of $14.7 million, which represents approximately 692,000 shares of common stock. Under the 2014 Plan, the performance share units will vest based on achieving Company financial performance metrics established at the outset of each three-year performance period. The metrics are a mix of cumulative revenue growth and cumulative EBITDA growth targets. The performance share units vest following the end of the three-year performance period based on achievement of the targets. The restricted stock awards will vest on the third anniversary of the date of grant subject to the participant's continued employment with the Company.
	Stock options were also granted as part of the IPO under the 2014 Plan for selected executives of the Company with an aggregate intrinsic value of $2.3 million, which represents approximately 509,000 shares of common stock. Each stock option vests in equal annual installments over a four-year period from the date of grant, contingent solely upon the participant's continued employment with the Company.
	The Company recognized equity-based compensation expense of $1.5 million and $1.2 million for the three months ended September 30, 2014 and September 30, 2013, respectively.

Other_Income_Expense_Notes

Other Income / Expense (Notes)	3 Months Ended
	Sep. 30, 2014
Other Income and Expenses [Abstract]	'
Other Income and Other Expense Disclosure [Text Block]	'
	OTHER (INCOME) / EXPENSE, NET
	The components of Other (Income) / Expense for the three months ended September 30, 2014 and 2013 are as follows:
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Other (Income) / Expense
	Debt extinguishment costs	$	20.6		$	0.1
	Gain on acquisition (1)	(7.0		)	—
	Sponsor advisory agreement termination fee (2)	29.8			—
	Foreign currency (gains) and losses	(3.1		)	(1.0		)
	Other	1			$	(0.1	)
	Total Other (Income) / Expense	$	41.3		$	(1.0	)
	-1	The Company completed a product acquisition in July 2014 that was accounted for as a business combination and resulted in a non-cash bargain purchase gain of $7.0 million.
	-2	The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with our IPO.

Redeemable_noncontrolling_inte

Redeemable noncontrolling interest	3 Months Ended
	Sep. 30, 2014
Temporary Equity Disclosure [Abstract]	'
Redeemable Noncontrolling Interest	'
	REDEEMABLE NONCONTROLLING INTEREST
	In July 2013, the Company acquired a 67% controlling interest in a softgel manufacturing facility located in Haining, China. The noncontrolling interest shareholders have the right to jointly sell the remaining 33% interest to Catalent during the 30-day period following the third anniversary of closing for a price based on the greater of (1) an amount that would provide the noncontrolling interest shareholders a return on their investment of a predetermined amount per annum on their pro rata share of the initial valuation or (2) a multiple of the sum of the target's earnings before interest, taxes, depreciation and amortization and amortization less net debt for the four quarters immediately preceding such sale. Noncontrolling interest with redemption features, such as the arrangement described above, that are not solely within the Company's control are considered redeemable noncontrolling interests, which is considered temporary equity and is therefore reported outside of permanent equity on the Company's consolidated balance sheet at the greater of the initial carrying amount adjusted for the noncontrolling interest's share of net income/(loss) or its redemption value. As of September 30, 2014, the redemption value of the redeemable noncontrolling interest approximated the carrying value.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	COMMITMENTS AND CONTINGENCIES
	As previously disclosed with regard to the Company’s participation in a multi-employer pension plan, the Company notified the plan trustees of its withdrawal from such plan in fiscal 2012. The withdrawal from the plan resulted in the recognition of liabilities associated with the Company’s long-term obligations in both the prior and current year periods, which were primarily recorded as an expense within discontinued operations. The actuarial review process, which is administered by the plan trustees, is ongoing and the Company awaits final determination as to the Company’s ultimate liability. The annual cash impact associated with the Company's long-term obligation approximates $1.7 million per year. Refer to Note 9 to the Consolidated Financial Statements for further discussion.
	Beginning in November 2006, the Company, along with several pharmaceutical companies, has been named in approximately 380 civil lawsuits filed by individuals allegedly injured by their use of the prescription acne medication Amnesteem®, a branded generic form of isotretinoin, and in some instances of isotretinoin products made and/or sold by other firms as well. All of these lawsuits have been dismissed or settled.
	From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant. The Company intends to vigorously defend itself against such other litigation and does not currently believe that the outcome of any such other litigation will have a material adverse effect on the Company’s financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise.
	From time to time, the Company receives subpoenas or requests for information from various government agencies, including from state attorneys general and the U.S. Department of Justice relating to the business practices of customers or suppliers. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred. The Company expects to incur costs in future periods in connection with existing and future requests.

Segment_Information

Segment Information	3 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	SEGMENT INFORMATION
	The Company conducts its business within the following operating segments: Softgel Technologies, Modified Release Technologies, Medication Delivery Solutions and Development & Clinical Services. The Softgel Technologies and Modified Release Technologies segments are aggregated into one reportable operating segment – Oral Technologies. The Company evaluates the performance of its segments based on segment earnings before noncontrolling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax (benefit)/expense, and depreciation and amortization (“Segment EBITDA”). EBITDA from continuing operations is consolidated earnings from continuing operations before interest expense, income tax (benefit)/expense, depreciation and amortization and is adjusted for the income or loss attributable to noncontrolling interest. The Company’s presentation of Segment EBITDA and EBITDA from continuing operations may not be comparable to similarly-titled measures used by other companies.
	The following tables include net revenue and Segment EBITDA during the three months ended September 30, 2014 and September 30, 2013:
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Oral Technologies
	Net revenue	$	261.1		$	258.9
	Segment EBITDA	57.7			60.4
	Medication Delivery Solutions
	Net revenue	56.9			56.5
	Segment EBITDA	9.9			8.2
	Development and Clinical Services
	Net revenue	103.1			101
	Segment EBITDA	21.4			15.7
	Inter-segment revenue elimination	(2.8		)	(2.1		)
	Unallocated Costs (1)	(52.4		)	(11.6		)
	Combined Totals:
	Net revenue	$	418.3		$	414.3
	EBITDA from continuing operations	$	36.6		$	72.7
	-1	Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Equity compensation	$	(1.5	)	$	(1.2	)
	Restructuring and other special items (2)	(4.5		)	(6.7		)
	Sponsor advisory fee	—			(3.2		)
	Noncontrolling interest	0.4			0.1
	Other income/(expense), net (3)	(41.3		)	1
	Non-allocated corporate costs, net	(5.5		)	(1.6		)
	Total unallocated costs	$	(52.4	)	$	(11.6	)
	-2	Segment results do not include restructuring and certain acquisition-related costs.
	-3	Amounts primarily relate to the expense associated with the termination of the sponsor advisory services agreement of $29.8 million in connection with the IPO, expenses related to financing transactions of $20.6 million, and acquisition-related gain of $7.0 million, all during the current year; and foreign currency translation gains and losses during all periods presented.
	Provided below is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations:
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Earnings/(loss) from continuing operations	$	(20.3	)	$	1.8
	Depreciation and amortization	35			36.5
	Interest expense, net	35.5			40.9
	Income tax (benefit)/expense	(14.0		)	(6.6		)
	Noncontrolling interest	0.4			0.1
	EBITDA from continuing operations	$	36.6		$	72.7
	The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the Consolidated Financial Statements:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Assets
	Oral Technologies	$	2,505.30		$	2,585.60
	Medication Delivery Solutions	291.4			292.8
	Development and Clinical Services	642.2			672.1
	Corporate and eliminations	(487.6		)	(460.3		)
	Total assets	$	2,951.30		$	3,090.20

Supplemental_Balance_Sheet_Inf

Supplemental Balance Sheet Information	3 Months Ended
	Sep. 30, 2014
Balance Sheet Related Disclosures [Abstract]	'
Supplemental Balance Sheet Information	'
	SUPPLEMENTAL BALANCE SHEET INFORMATION
	Supplementary balance sheet information at September 30, 2014 and June 30, 2014 is detailed in the following tables.
	Inventories
	Work-in-process and finished goods inventories include raw materials, labor, and overhead. Total inventories consist of the following:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Raw materials and supplies	$	86.8		$	84.1
	Work-in-process	25.6			23.8
	Finished goods	41.9			39.8
	Total inventories, gross	154.3			147.7
	Inventory reserve	(11.9		)	(12.9		)
	Inventories	$	142.4		$	134.8
	Prepaid expenses and other
	Prepaid expenses and other current assets consist of the following:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Prepaid expenses	$	25.2		$	16.6
	Spare parts supplies	12.1			12.5
	Deferred taxes	11.8			12.7
	Other current assets	32.2			32.8
	Prepaid expenses and other	$	81.3		$	74.6
	Property, plant, and equipment, net
	Property, plant, and equipment, net consist of the following:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Land, buildings, and improvements	$	603.3		$	619
	Machinery, equipment, and capitalized software	674			683.6
	Furniture and fixtures	8.8			8.1
	Construction in progress	121			110.9
	Property, plant, and equipment, at cost	1,407.10			1,421.60
	Accumulated depreciation	(553.8		)	(548.6		)
	Property, plant, and equipment, net	$	853.3		$	873
	Other assets
	Other assets consist of the following:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Deferred long term debt financing costs	$	9.9		$	19.7
	Other	25.8			29
	Total other assets	$	35.7		$	48.7
	Other accrued liabilities
	Other accrued liabilities consist of the following:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Accrued employee-related expenses	$	79.2		$	86.7
	Restructuring accrual	6.4			10.3
	Deferred income tax	0.9			1
	Accrued interest	0.5			12.2
	Deferred revenue and fees	40.1			47.1
	Accrued income tax	42.5			61.5
	Other accrued liabilities and expenses	54.9			60.9
	Other accrued liabilities	$	224.5		$	279.7

Subsequent_Events

Subsequent Events	3 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	SUBSEQUENT EVENTS
	In November 2014, the Company acquired 100% of the shares of a company specializing in particle size reduction (micronization), milling and analytical contract services on a global basis. The acquired business is based in the U.S. and the U.K. The acquired business will be included in the Development and Clinical Services segment.
	In October 2014, the Company acquired the remaining shares of Redwood Bioscience Inc., and the SMARTagAntibody-Drug Conjugate (ADC) technology platform. The acquired business is based in the U.S. and will be included in the Oral Technologies segment.
	The purchase price and financial results of the aforementioned acquired businesses are not material to the Company’s consolidated financial statements individually or in the aggregate.
	In the preparation of its consolidated financial statements, the Company completed an evaluation of the impact of subsequent events and determined there was no other subsequent event requiring disclosure in or adjustment to these financial statements.

Basis_of_Presentation_and_Summ1

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending June 30, 2015. The consolidated balance sheet at June 30, 2014 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2014 filed with the Securities and Exchange Commission.
	Noncontrolling interest is included within the equity section in the consolidated balance sheets. Redeemable noncontrolling interest has been classified as temporary equity and is therefore reported outside of permanent equity on the consolidated balance sheets at the greater of the initial carrying amount adjusted for the noncontrolling interest's share of net earnings/(loss) or its redemption value. The Company presents the amount of consolidated net earnings/(loss) that is attributable to Catalent and the noncontrolling interest in the consolidated statements of operations. Furthermore, the Company discloses the amount of comprehensive income that is attributable to Catalent and the noncontrolling interest in the consolidated statements of comprehensive income/(loss).
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, inventory and long-lived asset valuation, goodwill and other intangible asset valuation and impairment, equity-based compensation, income taxes, derivative financial instruments and pension plan asset and liability valuation. Actual amounts may differ from these estimated amounts.
Translation and Transaction of Foreign Currencies	'
	Foreign Currency Translation
	The financial statements of the Company’s operations outside the U.S. are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign operations into U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. The currency fluctuations related to certain long-term inter-company loans deemed to not be repayable in the foreseeable future have been recorded within the cumulative translation adjustment, a component of other comprehensive income/(loss). In addition, the currency fluctuation associated with the portion of the Company’s euro-denominated debt designated as a net investment hedge is included as a component of other comprehensive income/(loss). Foreign currency transaction gains and losses calculated by utilizing weighted average exchange rates for the period are included in the consolidated statements of operations in the other (income) expense, net line item. Foreign currency translation gains and losses generated from inter-company loans that are long-term in nature, but may be repayable in the foreseeable future, are also recorded within the other (income) expense, net line item on the consolidated statements of operations.
Revenue Recognition	'
	Revenue Recognition
	In accordance with Codification Standard ASC 605 Revenue Recognition, the Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. In cases where the Company has multiple contracts with the same customer, the Company evaluates those contracts to assess if the contracts are linked or are separate arrangements. Factors the Company considers include the timing of negotiation, interdependency with other contracts or elements and payment terms. The Company and its customers generally view each contract discussion as a separate arrangement.
	Manufacturing and packaging service revenue is recognized upon delivery of the product in accordance with the terms of the contract, which specify when transfer of title and risk of loss occurs. Some of the Company’s manufacturing contracts with its customers have annual minimum purchase requirements. At the end of the contract year, revenue is recognized for the unfilled purchase obligation in accordance with the contract terms. Development service contracts generally take the form of a fee-for-service arrangement. After the Company has evidence of an arrangement, the price is determinable and there is a reasonable expectation regarding payment, the Company recognizes revenue at the point in time the service obligation is completed and accepted by the customer. Examples of output measures include a formulation report, analytical and stability testing, clinical batch production or packaging and the storage and distribution of a customer’s clinical trial material. Development service revenue is primarily driven by the Company’s Development and Clinical Services segment.
	Arrangements containing multiple elements, including service arrangements, are accounted for in accordance with the provisions of ASC 605-25 Revenue Recognition: Multiple-Element Arrangements. The Company determines the separate units of account in accordance with ASC 605-25. If the deliverable meets the criteria of a separate unit of accounting, the arrangement consideration is allocated to each element based upon its relative selling price. In determining the best evidence of selling price of a unit of account the Company utilizes vendor-specific objective evidence (“VSOE”), which is the price the Company charges when the deliverable is sold separately. When VSOE is not available, management uses relevant third-party evidence (“TPE”) of selling price, if available. When neither VSOE nor TPE of selling price exists, management uses its best estimate of selling price.
Goodwill	'
	Goodwill
	The Company accounts for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350 Goodwill, Intangible and Other Assets. Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. The Company's annual goodwill impairment test was conducted as of April 1, 2014. The Company assesses goodwill for possible impairment by comparing the carrying value of its reporting units to their fair values. The Company determines the fair value of its reporting units utilizing estimated future discounted cash flows and incorporates assumptions that it believes marketplace participants would utilize. In addition, the Company uses comparative market information and other factors to corroborate the discounted cash flow results.
Property and Equipment and Other Definite Lived Intangible Assets	'
	Property and Equipment and Other Definite Lived Intangible Assets
	Property and equipment are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following ranges of useful lives for its property and equipment categories: buildings and improvements - 5 to 50 years; machinery and equipment - 3 to 10 years; and furniture and fixtures - 3 to 7 years. Depreciation expense was $23.7 million for the three months ended September 30, 2014 and $26.2 million for the three months ended September 30, 2013. Depreciation expense includes amortization of assets related to capital leases. The Company charges repairs and maintenance costs to expense as incurred. The amount of capitalized interest was immaterial for all periods presented.
	Intangible assets with finite lives, primarily including customer relationships and patents and trademarks continue to be amortized over their useful lives. The Company evaluates the recoverability of its other long-lived assets, including amortizing intangible assets, if circumstances indicate impairment may have occurred pursuant to ASC 360 Property, Plant and Equipment. This analysis is performed by comparing the respective carrying values of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, the carrying value of such assets is reduced to fair value through a charge to the consolidated statements of operations. Fair value is determined based on assumptions the Company believes marketplace participants would utilize and comparable marketplace information in similar arms length transactions.
Research and Development Expense, Policy	'
	Research and Development Costs
	The Company expenses research and development costs as incurred. Costs incurred in connection with the development of new offerings and manufacturing process improvements are recorded within selling, general and administrative expenses. Such research and development costs included in selling, general and administrative expenses amounted to $2.8 million for the three months ended September 30, 2014 and $3.4 million for the three months ended September 30, 2013. Costs incurred in connection with research and development services the Company provides to customers and services performed in support of the commercial manufacturing process for customers are recorded within cost of sales. Such research and development costs included in cost of sales amounted to $8.8 million for the three months ended September 30, 2014 and $7.4 million for the three months ended September 30, 2013.
Earnings Per Share, Policy	'
	Earnings / (Loss) Per Share
	The Company reports net earnings (loss) per share pursuant to ASC 260 Earnings per Share. Under ASC 260, basic earnings per share, which excludes dilution, is computed by dividing net earnings or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution of securities that could be exercised or converted into common shares, and is computed by dividing net earnings or loss available to common stockholders by the weighted average of common shares outstanding plus the dilutive potential common shares. Diluted earnings per share includes in-the-money stock options, restricted stock units, and restricted stock using the treasury stock method. During a loss period, the assumed exercise of in-the-money stock options has an anti-dilutive effect and therefore, these instruments are excluded from the computation of dilutive earnings per share.
Share-based Compensation, Option and Incentive Plans Policy	'
	Equity-Based Compensation
	The Company accounts for its equity-based compensation awards pursuant to ASC 718 Compensation-Stock Compensation. ASC 718 requires companies to recognize compensation expense using a fair value based method for costs related to share-based payments including stock options and restricted stock units. The expense is measured based on the grant date fair value of the awards that are expected to vest, and the expense is recorded over the applicable requisite service period. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price based on peer companies, the expected dividends on the underlying shares and the risk-free interest rate.
Recent Financial Accounting Standards	'
	Recent Financial Accounting Standards
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which explicitly requires management to assess an entity’s ability to continue as a going concern at each annual and interim reporting period, and to provide related footnote disclosures in certain circumstances. The standard indicates that substantial doubt exists when it is probable that an entity will not meet its obligations one year from the date the financial statements are issued. The likelihood threshold of probable is similar to its current use in US GAAP for loss contingencies. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier application is permitted. Catalent does not expect this standard to have a material impact on the Company's disclosures.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09").  The new standard will supersede nearly all existing revenue recognition guidance.  The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, the standard creates a five-step model that requires a company to exercise judgment when considering the terms of the contracts and all relevant facts and circumstances.  The five steps require a company to identify customer contracts, identify the separate performance obligations, determine the transaction price, allocate the transaction price to the separate performance obligations and recognize revenue when each performance obligation is satisfied. The standard is effective for public entities for annual and interim periods beginning after December 15, 2016.  The standard allows for either full retrospective adoption, where the standard is applied to all periods presented, or modified retrospective adoption where the standard is applied only to the most current period presented in the financial statements.  Early adoption is not permitted.  Catalent is currently evaluating the impact of this standard on the Company's consolidated results of operations and financial position.

Goodwill_Tables

Goodwill (Tables)	3 Months Ended
	Sep. 30, 2014
Goodwill Disclosure [Abstract]	'
Goodwill - Rollforward	'
	The following table summarizes the changes between June 30, 2014 and September 30, 2014 in the carrying amount of goodwill in total and by reporting segment:
	(Dollars in millions)	Oral			Medication		Development			Total
		Technologies			Delivery		& Clinical
					Solutions		Services
	Balance at June 30, 2014 (1)	$	891.8		$	—	$	205.3		$	1,097.10
	Additions/(impairments)	—			—		—			—
	Foreign currency translation adjustments	(32.0		)	—		(7.2		)	(39.2		)
	Balance at September 30, 2014	$	859.8		$	—	$	198.1		$	1,057.90
	-1	The opening balance is reflective of historical impairment charges related to the Medication Delivery Solutions segment of approximately $158.0 million.

Definite_Lived_LongLived_Asset1

Definite Lived Long-Lived Assets (Tables)	3 Months Ended
	Sep. 30, 2014
Intangible Assets Disclosure [Abstract]	'
Other Intangible Assets Subject to Amortization	'
	The details of other intangible assets subject to amortization as of September 30, 2014 and June 30, 2014, are as follows:
	(Dollars in millions)	Weighted Average Life		Gross				Accumulated				Net
				Carrying				Amortization				Carrying
				Value								Value
	30-Sep-14
	Amortized intangibles:
	Core technology	19 years		$	169.5			$	(53.5	)		$	116
	Customer relationships	14 years		229				(70.4		)		158.6
	Product relationships	12 years		230				(143.7		)		86.3
	Total intangible assets			$	628.5			$	(267.6	)		$	360.9
	(Dollars in millions)	Weighted Average Life		Gross				Accumulated				Net
				Carrying				Amortization				Carrying
				Value								Value
	30-Jun-14
	Amortized intangibles:
	Core technology	20 years		$	150.2			$	(53.3	)		$	96.9
	Customer relationships	14 years		234.6				(68.0		)		166.6
	Product relationships	12 years		237.6				(143.5		)		94.1
	Total intangible assets			$	622.4			$	(264.8	)		$	357.6
Future Amortization Expense	'
	(Dollars in millions)	Remainder				2016				2017				2018		2019		2020
		Fiscal 2015
	Amortization expense	$	33.7			$	44.9			$	44.3			$	44.2	$	38.6	$	23.3

LongTerm_Obligations_and_Other1

Long-Term Obligations and Other Short-Term Borrowings (Tables)	3 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Long-Term Obligations, Presented Net of Issue Discounts and Fees Paid to Lenders, and Other Short-Term Borrowings	'
	Long-term obligations and other short-term borrowings consist of the following at September 30, 2014 and June 30, 2014:
	(Dollars in millions)	Maturity	September 30,		June 30,
			2014		2014
	Senior Secured Credit Facilities
	Term loan facility dollar-denominated	May-21	1,381.00		1,383.90
	Term loan facility euro-denominated	May-21	315.6		338.6
	9 3/4 % Senior Subordinated euro-denominated Notes	Apr-17	—		293.9
	7 7/8 % Senior Notes	Oct-18	—		348.7
	Senior Unsecured Term Loan Facility	Dec-17	40.4		274.3
	$200.0 million Revolving Credit Facility	May-19	—		—
	Capital lease obligations	2015 to 2032	61.2		64
	Other obligations	2015 to 2018	18.5		7.2
	Total		1,816.70		2,710.60
	Less: Current portion of long-term obligations and other short-term borrowings		36.4		25.2
	Long-term obligations, less current portion		$	1,780.30	$	2,685.40

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	EARNINGS PER SHARE
	The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three months ended September 30, 2014 and 2013 are as follows (in millions, except per share data):
		Three months ended September 30,
	(Dollars in millions)	2014			2013
	Earnings / (loss) from continuing operations less net income / (loss) attributable to noncontrolling interest	$	(19.9	)	$	1.9
	Earnings / (loss) from discontinued operations	0.4			(0.4		)
	Net earnings / (loss) attributable to Catalent	$	(19.5	)	$	1.5
	Weighted average shares outstanding	105,535,385			75,015,223
	Dilutive securities issuable-stock plans	—			1,034,605
	Total weighted average diluted shares outstanding	105,535,385			76,049,828
	Basic earnings per share of common stock:
	Earnings / (loss) from continuing operations	$	(0.19	)	$	0.03
	Earnings / (loss) from discontinued operations	0.01			(0.01		)
	Net earnings / (loss) attributable to Catalent	$	(0.18	)	$	0.02
	Diluted earnings per share of common stock-assuming dilution:
	Earnings / (loss) from continuing operations	$	(0.19	)	$	0.02
	Earnings / (loss) from discontinued operations	0.01			—
	Net earnings / (loss) attributable to Catalent	$	(0.18	)	$	0.02

Fair_Value_Measurements_Of_Fin1

Fair Value Measurements Of Financial Instruments (Tables)	3 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Summary of Financial Assets and Liabilities That Measure at Fair Value on a Recurring Basis	'
	The following table provides a summary of financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall:
				Fair Value Measurements using:
	(Dollars in millions)	Total		Level 1		Level 2		Level 3
	Assets
	Cash equivalents - money market funds	$	4.1	$	4.1	$	—	$	—
	The following table provides a summary of financial assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2014, aggregated by the level in the fair value hierarchy in which those measurements fall:
				Fair Value Measurements using:
	(Dollars in millions)	Total		Level 1		Level 2		Level 3
	Assets
	Cash equivalents - money market funds	$	1.4	$	1.4	$	—	$	—
	Liabilities
	Contingent consideration	$	0.9	$	—	$	—	$	0.9
Carrying Amounts and Estimated Fair Values of Financial Instruments	'
	The carrying amounts and the estimated fair values of financial instruments as of September 30, 2014 and June 30, 2014, are as follows:
		30-Sep-14				30-Jun-14
	(Dollars in millions)	Carrying		Estimated Fair		Carrying		Estimated Fair
		Value		Value		Value		Value
	Long-term debt and other	$	1,816.70	$	1,839.30	$	2,710.60	$	2,680.20

Income_Taxes_Income_Taxes_Tabl

Income Taxes Income Taxes (Tables)	3 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]	'
	A reconciliation of its reserves for uncertain tax positions, excluding accrued interest and penalties, for September 30, 2014 is as follows:
	(Dollars in millions)
	Balance at June 30, 2014	$	60.6
	Reductions based on tax positions related to the current year	(1.8		)
	Reductions for tax positions of prior years	(2.4		)
	Balance at September 30, 2014	$	56.4

Employee_Retirement_Benefit_Pl1

Employee Retirement Benefit Plans (Tables)	3 Months Ended
	Sep. 30, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Components of Company's Net Periodic Benefit Costs	'
	Components of the Company’s net periodic benefit costs are as follows:
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Components of net periodic benefit cost:
	Service cost	$	0.7		$	0.7
	Interest cost	3.1			3
	Expected return on plan assets	(2.8		)	(2.5		)
	Amortization (1)	0.5			0.3
	Net amount recognized	$	1.5		$	1.5
	-1	Amount represents the amortization of unrecognized actuarial gains/(losses).

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Schedule of Comprehensive Income (Loss)	'
	The components of the changes in the cumulative translation adjustment and minimum pension liability for the three months ended September 30, 2014 and September 30, 2013 are presented below.
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Foreign currency translation adjustments:
	Net investment hedge	$	10.8		$	(11.4	)
	Long term intercompany loans	(9.6		)	12.2
	Translation adjustments	(55.4		)	19.6
	Total foreign currency translation adjustment, pre tax	(54.2		)	20.4
	Tax expense/(benefit)	(0.4		)	—
	Total foreign currency translation adjustment, net of tax	$	(53.8	)	$	20.4
	Net change in minimum pension liability
	Net gain/(loss) recognized during the period	0.5			0.3
	Total pension, pretax	0.5			0.3
	Tax expense/(benefit)	(0.1		)	(0.1		)
	Net change in minimum pension liability, net of tax	$	0.4		$	0.2
Schedule of Accumulated Other Comprehensive Income (Loss)	'
	For the three months ended September 30, 2014 the changes in accumulated other comprehensive income net of tax by component are as follows:
	(Dollars in millions)	Foreign Exchange Translation Adjustments			Pension and Other Post-Retirement Adjustments			Deferred Compensation			Total
	Balance at June 30, 2014	$	14		$	(41.4	)	$	3.2		$	(24.2	)
	Other comprehensive income/(loss) before reclassifications	(53.8		)	—			(0.2		)	(54.0		)
	Amounts reclassified from accumulated other comprehensive income	—			0.4			—			0.4
	Net current period other comprehensive income (loss)	(53.8		)	0.4			(0.2		)	(53.6		)
	Balance at September 30, 2014	$	(39.8	)	$	(41.0	)	$	3		$	(77.8	)
	For the three months ended September 30, 2014, the Company reclassified $0.4 million of actuarial losses (net of tax benefit of $0.1 million) related to its defined benefit pension and other post-retirement benefit plans from accumulated other comprehensive income into selling, general and administrative expenses.

Other_Income_Expense_Tables

Other Income / Expense (Tables)	3 Months Ended
	Sep. 30, 2014
Other Income and Expenses [Abstract]	'
Schedule of Other Nonoperating Income (Expense)	'
	The components of Other (Income) / Expense for the three months ended September 30, 2014 and 2013 are as follows:
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Other (Income) / Expense
	Debt extinguishment costs	$	20.6		$	0.1
	Gain on acquisition (1)	(7.0		)	—
	Sponsor advisory agreement termination fee (2)	29.8			—
	Foreign currency (gains) and losses	(3.1		)	(1.0		)
	Other	1			$	(0.1	)
	Total Other (Income) / Expense	$	41.3		$	(1.0	)

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Net Revenue and Segment EBITDA	'
	The following tables include net revenue and Segment EBITDA during the three months ended September 30, 2014 and September 30, 2013:
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Oral Technologies
	Net revenue	$	261.1		$	258.9
	Segment EBITDA	57.7			60.4
	Medication Delivery Solutions
	Net revenue	56.9			56.5
	Segment EBITDA	9.9			8.2
	Development and Clinical Services
	Net revenue	103.1			101
	Segment EBITDA	21.4			15.7
	Inter-segment revenue elimination	(2.8		)	(2.1		)
	Unallocated Costs (1)	(52.4		)	(11.6		)
	Combined Totals:
	Net revenue	$	418.3		$	414.3
	EBITDA from continuing operations	$	36.6		$	72.7
	-1	Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Equity compensation	$	(1.5	)	$	(1.2	)
	Restructuring and other special items (2)	(4.5		)	(6.7		)
	Sponsor advisory fee	—			(3.2		)
	Noncontrolling interest	0.4			0.1
	Other income/(expense), net (3)	(41.3		)	1
	Non-allocated corporate costs, net	(5.5		)	(1.6		)
	Total unallocated costs	$	(52.4	)	$	(11.6	)
	-2	Segment results do not include restructuring and certain acquisition-related costs.
	-3	Amounts primarily relate to the expense associated with the termination of the sponsor advisory services agreement of $29.8 million in connection with the IPO, expenses related to financing transactions of $20.6 million, and acquisition-related gain of $7.0 million, all during the current year; and foreign currency translation gains and losses during all periods presented.
Reconciliation of Earnings/(loss) from Continuing Operations to EBITDA	'
	Provided below is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations:
		Three Months Ended
		September 30,
	(Dollars in millions)	2014			2013
	Earnings/(loss) from continuing operations	$	(20.3	)	$	1.8
	Depreciation and amortization	35			36.5
	Interest expense, net	35.5			40.9
	Income tax (benefit)/expense	(14.0		)	(6.6		)
	Noncontrolling interest	0.4			0.1
	EBITDA from continuing operations	$	36.6		$	72.7
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements	'
	The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the Consolidated Financial Statements:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Assets
	Oral Technologies	$	2,505.30		$	2,585.60
	Medication Delivery Solutions	291.4			292.8
	Development and Clinical Services	642.2			672.1
	Corporate and eliminations	(487.6		)	(460.3		)
	Total assets	$	2,951.30		$	3,090.20

Supplemental_Balance_Sheet_Inf1

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Sep. 30, 2014
Balance Sheet Related Disclosures [Abstract]	'
Work-in-Process and Finished Goods Inventories Include Raw Materials, Labor and Overhead	'
	Work-in-process and finished goods inventories include raw materials, labor, and overhead. Total inventories consist of the following:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Raw materials and supplies	$	86.8		$	84.1
	Work-in-process	25.6			23.8
	Finished goods	41.9			39.8
	Total inventories, gross	154.3			147.7
	Inventory reserve	(11.9		)	(12.9		)
	Inventories	$	142.4		$	134.8
Prepaid and Other Assets	'
	Prepaid expenses and other current assets consist of the following:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Prepaid expenses	$	25.2		$	16.6
	Spare parts supplies	12.1			12.5
	Deferred taxes	11.8			12.7
	Other current assets	32.2			32.8
	Prepaid expenses and other	$	81.3		$	74.6
Property and Equipment	'
	Property, plant, and equipment, net consist of the following:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Land, buildings, and improvements	$	603.3		$	619
	Machinery, equipment, and capitalized software	674			683.6
	Furniture and fixtures	8.8			8.1
	Construction in progress	121			110.9
	Property, plant, and equipment, at cost	1,407.10			1,421.60
	Accumulated depreciation	(553.8		)	(548.6		)
	Property, plant, and equipment, net	$	853.3		$	873
Other Assets Non Current	'
	Other assets consist of the following:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Deferred long term debt financing costs	$	9.9		$	19.7
	Other	25.8			29
	Total other assets	$	35.7		$	48.7
Other Accrued Liabilities	'
	Other accrued liabilities consist of the following:
	(Dollars in millions)	September 30,			June 30,
		2014			2014
	Accrued employee-related expenses	$	79.2		$	86.7
	Restructuring accrual	6.4			10.3
	Deferred income tax	0.9			1
	Accrued interest	0.5			12.2
	Deferred revenue and fees	40.1			47.1
	Accrued income tax	42.5			61.5
	Other accrued liabilities and expenses	54.9			60.9
	Other accrued liabilities	$	224.5		$	279.7

Basis_of_Presentation_and_Summ2

Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies - Business (Details) (USD $)	0 Months Ended					1 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 09, 2014	Aug. 05, 2014	Jul. 17, 2014	Sep. 09, 2014	Aug. 05, 2014	Aug. 31, 2014
						Investor [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	'	'	70	'	'	'
Stock Issued During Period, Shares, New Issues	6.4	42.5	'	'	'	'
Share Price	'	'	'	$20.50	$20.50	'
Proceeds from Issuance Initial Public Offering, Gross	'	$871.30	'	'	'	'
Proceeds from Issuance Initial Public Offering	124.2	828	'	'	'	'
Loss on Contract Termination	'	'	'	'	'	$29.80

Basis_of_Presentation_and_Summ3

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Line Items]	'	'
Depreciation expense	$23.70	$26.20
Building And Improvements [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives of property and equipment	'5 years	'
Building And Improvements [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives of property and equipment	'50 years	'
Machinery and Equipment [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives of property and equipment	'3 years	'
Machinery and Equipment [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives of property and equipment	'10 years	'
Furniture and Fixtures [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives of property and equipment	'3 years	'
Furniture and Fixtures [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives of property and equipment	'7 years	'

Basis_of_Presentation_and_Summ4

Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Selling, General and Administrative Expenses [Member]	'	'
Research and Development Expense [Line Items]	'	'
Research and Development Expense	$2.80	$3.40
Cost of Sales [Member]	'	'
Research and Development Expense [Line Items]	'	'
Research and Development Expense	$8.80	$7.40

Goodwill_Rollforward_Detail

Goodwill - Rollforward (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Jun. 30, 2014
Goodwill [Roll Forward]	'		'
Beginning balance	$1,097.10	[1]	'
Additions/(impairments)	0		'
Foreign currency translation adjustments	-39.2		'
Ending balance	1,057.90		'
Oral Technologies [Member]	'		'
Goodwill [Roll Forward]	'		'
Beginning balance	891.8	[1]	'
Additions/(impairments)	0		'
Foreign currency translation adjustments	-32		'
Ending balance	859.8		'
Medication Delivery Solutions [Member]	'		'
Goodwill [Line Items]	'		'
Goodwill, Impaired, Accumulated Impairment Loss	'		158
Goodwill [Roll Forward]	'		'
Beginning balance	0	[1]	'
Additions/(impairments)	0		'
Foreign currency translation adjustments	0		'
Ending balance	0		'
Development and Clinical Services [Member]	'		'
Goodwill [Roll Forward]	'		'
Beginning balance	205.3	[1]	'
Additions/(impairments)	0		'
Foreign currency translation adjustments	-7.2		'
Ending balance	$198.10		'
[1]	The opening balance is reflective of historical impairment charges related to the Medication Delivery Solutions segment of approximately $158.0 million.

Definite_Lived_LongLived_Asset2

Definite Lived Long-Lived Assets - Other Intangible Assets Subject to Amortization (Detail) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014
Product Rights [Line Items]	'	'
Gross Carrying Value	$628.50	$622.40
Accumulated Amortization	-267.6	-264.8
Net Carrying Value	360.9	357.6
Core technology [Member]	'	'
Product Rights [Line Items]	'	'
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	'19 years	'20 years
Gross Carrying Value	169.5	150.2
Accumulated Amortization	-53.5	-53.3
Net Carrying Value	116	96.9
Customer relationships [Member]	'	'
Product Rights [Line Items]	'	'
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	'14 years	'14 years
Gross Carrying Value	229	234.6
Accumulated Amortization	-70.4	-68
Net Carrying Value	158.6	166.6
Product relationships [Member]	'	'
Product Rights [Line Items]	'	'
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	'12 years	'12 years
Gross Carrying Value	230	237.6
Accumulated Amortization	-143.7	-143.5
Net Carrying Value	$86.30	$94.10

Definite_Lived_LongLived_Asset3

Definite Lived Long-Lived Assets - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Intangible Assets Disclosure [Abstract]	'	'
Amortization expense	$11.30	$10.30

Definite_Lived_LongLived_Asset4

Definite Lived Long-Lived Assets - Future Amortization Expense (Detail) (USD $)	Sep. 30, 2014
In Millions, unless otherwise specified
Intangible Assets Disclosure [Abstract]	'
Remainder Fiscal 2015	$33.70
2016	44.9
2017	44.3
2018	44.2
2019	38.6
2020	$23.30

LongTerm_Obligations_and_Other2

Long-Term Obligations and Other Short-Term Borrowings - Long-Term Obligations, Presented Net of Issue Discounts and Fees Paid to Lenders, and Other Short-Term Borrowings (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Schedule Of Debt [Line Items]	'	'
Debt, Current	$36.40	$25.20
Long-term Debt and Capital Lease Obligations	1,780.30	2,685.40
Term Loan Three Facility Dollar Denominated [Member]	'	'
Schedule Of Debt [Line Items]	'	'
Debt and Capital Lease Obligations	1,381	1,383.90
Term Loan Three Facility Euro Denominated [Member]	'	'
Schedule Of Debt [Line Items]	'	'
Debt and Capital Lease Obligations	315.6	338.6
Nine Point Seven Five Percent Senior Subordinated Euro Denominated Notes [Member]	'	'
Schedule Of Debt [Line Items]	'	'
Debt and Capital Lease Obligations	0	293.9
Seven Point Eight Seven Five Percent Senior Notes [Member]	'	'
Schedule Of Debt [Line Items]	'	'
Debt and Capital Lease Obligations	0	348.7
Senior Unsecured Term Loan Facility [Member]	'	'
Schedule Of Debt [Line Items]	'	'
Debt and Capital Lease Obligations	40.4	274.3
Revolving Credit Facility [Member]	'	'
Schedule Of Debt [Line Items]	'	'
Debt and Capital Lease Obligations	0	0
Capital Lease Obligations [Member]	'	'
Schedule Of Debt [Line Items]	'	'
Debt and Capital Lease Obligations	61.2	64
Other Obligations [Member]	'	'
Schedule Of Debt [Line Items]	'	'
Debt and Capital Lease Obligations	18.5	7.2
Carrying Value [Member]	'	'
Schedule Of Debt [Line Items]	'	'
Debt and Capital Lease Obligations	$1,816.70	$2,710.60

LongTerm_Obligations_and_Other3

Long-Term Obligations and Other Short-Term Borrowings Long-Term Obligations and Other Short-Term Borrowings (Details)	3 Months Ended		0 Months Ended					1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Aug. 28, 2014	Sep. 04, 2014	Sep. 04, 2014	Sep. 12, 2014	Aug. 06, 2014	Sep. 12, 2014
	USD ($)	USD ($)	Seven Point Eight Seven Five Percent Senior Notes [Member]	Nine Point Seven Five Percent Senior Subordinated Euro Denominated Notes [Member]	Nine Point Seven Five Percent Senior Subordinated Euro Denominated Notes [Member]	Other Obligations [Member]	Other Obligations [Member]	Other Obligations [Member]
			USD ($)	USD ($)	EUR (€)	USD ($)	USD ($)	USD ($)
Proceeds from (Payments for) Deposits Applied to Debt Retirements	'	'	$350	'	€ 225	$120	$114.50	'
Debt Instrument, Redemption Price, Percentage	'	'	101.50%	101.63%	101.63%	'	'	'
Call Premium Paid For Redemption Of Debt	9.8	0	5.3	4.5	'	'	'	'
Unamortized Deferred Financing Costs Written Off	'	'	$5.90	$4	'	'	'	$0.90

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'
Earnings/(loss) from continuing operations less net income (loss) attributable to noncontrolling interest	($19.90)	$1.90
Net earnings/(loss) from discontinued operations, net of tax	0.4	-0.4
Net Income (Loss) Attributable to Parent	($19.50)	$1.50
Weighted Average Number of Shares Outstanding, Basic	105,535,385	75,015,223
Weighted Average Number Diluted Shares Outstanding Adjustment	0	1,034,605
Weighted Average Number of Shares Outstanding, Diluted	105,535,385	76,049,828
Income (Loss) from Continuing Operations, Per Basic Share	($0.19)	$0.03
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	$0.01	($0.01)
Earnings Per Share, Basic	($0.18)	$0.02
Income (Loss) from Continuing Operations, Per Diluted Share	($0.19)	$0.02
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share	$0.01	$0
Earnings Per Share, Diluted	($0.18)	$0.02

Earnings_Per_Share_Earnings_Pe

Earnings Per Share Earnings Per Share - Additional Details (Details) (Stock Compensation Plan [Member])	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6.8	2.4
Restricted Stock Units (RSUs) [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1.4	'

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activities - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Derivative [Line Items]	'	'
Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)	$10.80	($11.40)
Net investment hedge	'	-11.4
Net accumulated gain related to investment hedges	60.2	'
Unrealized foreign exchange gain(loss)	21.3	-7.6
Hedge of a Net Investment In Foreign Operations [Member]	'	'
Derivative [Line Items]	'	'
Total long-term debt	$315.60	'

Recovered_Sheet1

Fair Value Measurements of Financial Instruments - Summary of Financial Assets and Liabilities That Measure at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Assets	'	'
Cash Equivalents - Money Market Funds	$4.10	$1.40
Business Combination, Contingent Consideration, Liability	'	0.9
Level 1 [Member]	'	'
Assets	'	'
Cash Equivalents - Money Market Funds	4.1	1.4
Business Combination, Contingent Consideration, Liability	'	0
Level 2 [Member]	'	'
Assets	'	'
Cash Equivalents - Money Market Funds	0	0
Business Combination, Contingent Consideration, Liability	'	0
Level 3 [Member]	'	'
Assets	'	'
Cash Equivalents - Money Market Funds	0	0
Business Combination, Contingent Consideration, Liability	'	$0.90

Recovered_Sheet2

Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Values of Financial Instruments (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Carrying Value [Member]	'	'
Fair Value Measurements Of Financial Instruments [Line Items]	'	'
Debt and Capital Lease Obligations	$1,816.70	$2,710.60
Estimated Fair Value [Member]	'	'
Fair Value Measurements Of Financial Instruments [Line Items]	'	'
Debt Instrument, Fair Value Disclosure	$1,839.30	$2,680.20

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Income Tax Contingency [Line Items]	'	'
Unrecognized Tax Benefits	$56.40	$60.60
Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued	61.7	65.7
Unrecognized tax benefits that impact the effective income tax rate	41	41.4
Accrued interest related to uncertain tax positions	5.4	5.1
Interest and penalties subject to indemnification	2	2
Former Owner [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Unrecognized Tax Benefits	$2.30	$2.40

Income_Taxes_Income_Tax_Disclo

Income Taxes Income Tax Disclosure (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'
Beginning Balance	$60.60
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions	-1.8
Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions	-2.4
Ending Balance	$56.40

Employee_Retirement_Benefit_Pl2

Employee Retirement Benefit Plans - Components of Company's Net Periodic Benefit Costs (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013		Jun. 30, 2014
Components of net periodic benefit cost:	'		'		'
Service cost	$0.70		$0.70		'
Interest cost	3.1		3		'
Expected return on plan assets	-2.8		-2.5		'
Amortization	0.5	[1]	0.3	[1]	'
Net amount recognized	1.5		1.5		'
Withdrawal obligation	39.6		'		'
Estimated discounted value of future employer contributions	39.6		'		39.6
Estimated annual cash contribution	$1.70		'		'
[1]	Amount represents the amortization of unrecognized actuarial gains/(losses).

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended				1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013		Aug. 31, 2014
					Investor [Member]
(Gain) / Loss on Contract Termination	$29.80	[1]	$0	[1]	$29.80
Management Fee Expense	$0		$3.20		'
[1]	The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with our IPO.

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Foreign currency translation adjustments:	'	'
Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)	$10.80	($11.40)
Long term intercompany loans	-9.6	12.2
Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)	-55.4	19.6
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax	-54.2	20.4
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	-0.4	0
Total foreign currency translation adjustment, pre tax	-53.8	20.4
Net change in minimum pension liability	'	'
Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax	0.5	0.3
Total pension, pretax	0.5	0.3
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	-0.1	-0.1
Net change in minimum pension liability, net of tax	$0.40	$0.20

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income (Loss)-Rollforward (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'
Beginning Balance	($24.20)	'
Other comprehensive income/(loss) before reclassifications	-54	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	-0.4	'
Net current period other comprehensive income (loss)	-53.6	21.1
Ending Balance	-77.8	'
Accumulated Translation Adjustment [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'
Beginning Balance	14	'
Other comprehensive income/(loss) before reclassifications	-53.8	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	'
Net current period other comprehensive income (loss)	-53.8	'
Ending Balance	-39.8	'
Accumulated Defined Benefit Plans Adjustment [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'
Beginning Balance	-41.4	'
Other comprehensive income/(loss) before reclassifications	0	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	-0.4	'
Net current period other comprehensive income (loss)	0.4	'
Ending Balance	-41	'
Accumulated Deferred Compensation [Member]	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'
Beginning Balance	3.2	'
Other comprehensive income/(loss) before reclassifications	-0.2	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	'
Net current period other comprehensive income (loss)	-0.2	'
Ending Balance	$3	'

Equity_and_Accumulated_Other_C

Equity and Accumulated Other Comprehensive Income (Loss) Equity (Details) (USD $)	0 Months Ended		3 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 09, 2014	Aug. 05, 2014	Sep. 30, 2014	Sep. 09, 2014	Aug. 05, 2014	Jun. 30, 2014
			vote
Equity [Abstract]	'	'	'	'	'	'
Common Stock, Shares Authorized	'	'	1,000,000,000	'	'	84,000,000
Common Stock, Par or Stated Value Per Share	'	'	$0.01	'	'	$0.01
Preferred Stock, Shares Authorized	'	'	100,000,000	'	'	0
Preferred Stock, Par or Stated Value Per Share	'	'	$0.01	'	'	'
Common Stock, Number of Votes per Share	'	'	1	'	'	'
Stock Issued During Period, Shares, New Issues	6,400,000	42,500,000	'	'	'	'
Share Price	'	'	'	$20.50	$20.50	'
Proceeds from Issuance Initial Public Offering, Gross	'	$871.30	'	'	'	'
Proceeds from Issuance Initial Public Offering	$124.20	$828	'	'	'	'

Equity_Based_Compensation_Deta

Equity Based Compensation (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Jul. 31, 2014
			Stock Compensation Plan - Omnibus [Member]	Stock Compensation Plan - Omnibus [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'5 years	'	'4 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	'	6,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value of Granted Shares	'	'	$14.70	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	692,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	'	'	2.3	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	'	509,000	'
Equity compensation	$1.50	$1.20	'	'

Other_Income_Expense_Details

Other Income / Expense (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013
Other Income and Expenses [Abstract]	'		'
Extinguishment of Debt, Gain (Loss), Net of Tax	$20.60		$0.10
Business Combination, Bargain Purchase, Gain Recognized, Amount	-7	[1]	0	[1]
(Gain) / Loss on Contract Termination	29.8	[2]	0	[2]
Foreign Currency Transaction (Gain) / Loss, Unrealized	-3.1		-1
Other Nonoperating (Income) Expense	1		-0.1
Nonoperating Income (Expense)	($41.30)		$1
[1]	-1
[2]	The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with our IPO.

Redeemable_noncontrolling_inte1

Redeemable noncontrolling interest (Details) (Softgel Manufacturing Facility [Member])	Jul. 31, 2013
Softgel Manufacturing Facility [Member]	'
Business Acquisition [Line Items]	'
Equity interest in acquiree (percent)	67.00%
Ownership percentage by noncontrolling owners (percent)	33.00%

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	Sep. 30, 2014
In Millions, unless otherwise specified	Cases
Commitments and Contingencies Disclosure [Abstract]	'
Estimated annual cash contribution	$1.70
Loss contingency, dismissed or settled claims (cases)	380

Segment_Information_Net_Revenu

Segment Information - Net Revenue and Segment Ebitda (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]	'		'
Net revenue	$418.30		$414.30
Segment EBITDA	36.6		72.7
Inter-segment revenue elimination	-2.8		-2.1
Unallocated Costs	-52.4	[1]	-11.6	[1]
Equity compensation	-1.5		-1.2
Restructuring and other special items (2)	-4.5	[2]	-6.7	[2]
Management Fee Expense	0		3.2
Noncontrolling interest	0.4		0.1
Other income (expense), net	-41.3	[3]	1	[3]
Non-allocated corporate costs, net	-5.5		-1.6
Total unallocated costs	-52.4	[1]	-11.6	[1]
(Gain) / Loss on Contract Termination	29.8	[4]	0	[4]
Extinguishment of Debt, Gain (Loss), Net of Tax	-20.6		-0.1
Business Combination, Bargain Purchase, Gain Recognized, Amount Net of Tax	7	[5]	0	[5]
Oral Technologies [Member]	'		'
Segment Reporting, Revenue Reconciling Item [Line Items]	'		'
Net revenue	261.1		258.9
Segment EBITDA	57.7		60.4
Medication Delivery Solutions [Member]	'		'
Segment Reporting, Revenue Reconciling Item [Line Items]	'		'
Net revenue	56.9		56.5
Segment EBITDA	9.9		8.2
Development and Clinical Services [Member]	'		'
Segment Reporting, Revenue Reconciling Item [Line Items]	'		'
Net revenue	103.1		101
Segment EBITDA	$21.40		$15.70
[1]	Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:B Three Months Ended September 30,(Dollars in millions)2014B 2013Equity compensation$(1.5)B $(1.2)Restructuring and other special items (2)(4.5)B (6.7)Sponsor advisory feebB (3.2)Noncontrolling interest0.4B 0.1Other income/(expense), net (3)(41.3)B 1.0Non-allocated corporate costs, net(5.5)B (1.6)Total unallocated costs$(52.4)B $(11.6)
[2]	Segment results do not include restructuring and certain acquisition-related costs
[3]	Amounts primarily relate to the expense associated with the termination of the sponsor advisory services agreement of $29.8 million in connection with the IPO, expenses related to financing transactions of $20.6 million, and acquisition-related gain of $7.0 million, all during the current year; and foreign currency translation gains and losses during all periods presented.
[4]	The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with our IPO.
[5]	-1

Segment_Information_Reconcilia

Segment Information - Reconciliation of Earnings / (Loss) from Continuing Operations to Ebitda (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting [Abstract]	'	'
Earnings/(loss) from continuing operations	($20.30)	$1.80
Depreciation and amortization	35	36.5
Interest expense, net	35.5	40.9
Income tax (benefit)/expense	-14	-6.6
Noncontrolling interest	0.4	0.1
EBITDA from continuing operations	$36.60	$72.70

Segment_Information_Total_Asse

Segment Information - Total Assets for Each Segment and Reconciling in Consolidated Financial Statements (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	$2,951.30	$3,090.20
Oral Technologies [Member]	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	2,505.30	2,585.60
Medication Delivery Solutions [Member]	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	291.4	292.8
Development and Clinical Services [Member]	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	642.2	672.1
Corporate and Eliminations [Member]	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Total assets	($487.60)	($460.30)

Supplemental_Balance_Sheet_Inf2

Supplemental Balance Sheet Information - Inventory (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Inventory, Net [Abstract]	'	'
Raw materials and supplies	$86.80	$84.10
Work-in-process	25.6	23.8
Finished goods	41.9	39.8
Total inventories, gross	154.3	147.7
Inventory reserve	-11.9	-12.9
Inventories	$142.40	$134.80

Supplemental_Balance_Sheet_Inf3

Supplemental Balance Sheet Information - Prepaid and Other Assets (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Prepaid Expense and Other Assets, Current [Abstract]	'	'
Prepaid Expense, Current	$25.20	$16.60
Spare parts supplies	12.1	12.5
Deferred taxes	11.8	12.7
Other current assets	32.2	32.8
Prepaid expenses and other	$81.30	$74.60

Supplemental_Balance_Sheet_Inf4

Supplemental Balance Sheet Information - Property and Equipment (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Property, Plant and Equipment, Net [Abstract]	'	'
Land Buildings And Improvements	$603.30	$619
Machinery, equipment, and capitalized software	674	683.6
Furniture and fixtures	8.8	8.1
Construction in progress	121	110.9
Property, plant, and equipment, at cost	1,407.10	1,421.60
Accumulated depreciation	-553.8	-548.6
Property, plant, and equipment, net	$853.30	$873

Supplemental_Balance_Sheet_Inf5

Supplemental Balance Sheet Information - Other Assets Non Current (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Other Assets, Noncurrent [Abstract]	'	'
Deferred long term debt financing costs	$9.90	$19.70
Other Assets, Miscellaneous, Noncurrent	25.8	29
Other Assets, Noncurrent	$35.70	$48.70

Supplemental_Balance_Sheet_Inf6

Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Accrued employee-related expenses	$79.20	$86.70
Restructuring accrual	6.4	10.3
Deferred income tax	0.9	1
Accrued interest	0.5	12.2
Deferred revenue and fees	40.1	47.1
Accrued income tax	42.5	61.5
Other accrued liabilities and expenses	54.9	60.9
Other accrued liabilities	$224.50	$279.70